Glycosaminoglycan sulodexide inhibition of MMP-9 gelatinase secretion and activity: Possible pharmacological role against collagen degradation in vascular chronic diseases

Current Vascular Pharmacology

Volumn 11, Issue 3, 2013, Pages 354-365

  Mannello, Ferdinando ^a   Medda, Virginia ^a   Ligi, Daniela ^a   Raffetto, Joseph D ^b,c  

^a UNIVERSITY OF URBINO   (Italy)

^b VA BOSTON HEALTHCARE SYSTEM   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Chronic venous disease; Dermatan sulphate; Glycosaminoglycan; Matrix metalloproteinases; Plasma; Sulodexide; U937 cell line

Indexed keywords

GELATINASE A; GELATINASE B; GLYCOSAMINOGLYCAN SULODEXIDE; MATRIX METALLOPROTEINASE; SULODEXIDE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CELL CULTURE; CELL VIABILITY; COLLAGEN DEGRADATION; DENSITOMETRY; ELECTROPHORESIS; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; MALE; NORMAL HUMAN; PROSPECTIVE STUDY; PROTEIN DEGRADATION; PROTEIN EXPRESSION; SPECTROMETRY; VASCULAR DISEASE; ZYMOGRAPHY;

ADULT; CHRONIC DISEASE; COLLAGEN; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLYCOSAMINOGLYCANS; HUMANS; LEUKEMIA; LEUKOCYTES; MALE; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASE INHIBITORS; MIDDLE AGED; PROSPECTIVE STUDIES; U937 CELLS; VASCULAR DISEASES;

EID: 84878632582     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/1570161111311030010     Document Type: Article

References (50)

1. Page-McCaw A, Ewald AJ, Werb Z. Matrix metalloproteinases and the regulation of tissue remodelling. Nat Rev Mol Cell Biol 2007; 8: 221-233.
2. Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regu-lators of the tumor microenvironment. Cell 2010; 14: 52-67.
3. Mannello F, Luchetti F, Falcieri E, Papa S. Multiple roles of matrix metalloproteinases during apoptosis. Apoptosis 2005; 10: 19-24.
4. Hadler-Olsen E, Fadnes B, Sylte I, Uhlin-Hansen L, Winberg JO. Regulation of matrix metalloproteinase activity in health and disease. FEBS J 2011; 278: 28-45.
5. Mannello F, Gazzanelli G. Tissue inhibitors of metalloproteinases and programmed cell death: conundrums, controversies and potential implications. Apoptosis 2001; 6: 479-482.
6. Cauwe B, Van den Steen PE, Opdenakker G. The biochemical, biological, and pathological kaleidoscope of cell surface substrates processed by matrix metalloproteinases. Crit Rev Biochem Mol Biol 2007; 42: 113-185.
7. Roy R, Yang J, Moses MA. Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. J Clin Oncol 2009; 27: 5287-5297.
8. Mannello F. Natural bio-drugs as matrix metalloproteinase inhibi-tors: new perspectives on the horizon? Recent Pat Anticancer Drug Discov 2006; 1: 91-103.
9. Mannello F, Tonti G, Papa S. Matrix metalloproteinase inhibitors as anticancer therapeutics. Curr Cancer Drug Targets 2005; 5: 285-298.
10. Dorman G, Cseh S, Hajdu I, et al. Matrix metalloproteinase inhibitors: a critical appraisal of design principles and proposed therapeutic utility. Drugs 2010; 70: 949-964.
11. Kupai K, Szucs G, Cseh S, et al. Matrix metalloproteinase activity assays: Importance of zymography. J Pharmacol Toxicol Methods 2010; 61: 205-209.
12. Zucker S, Doshi K, Cao J. Measurement of matrix metalloprotein-ases (MMPs) and tissue inhibitors of metalloproteinases (TIMP) in blood and urine: potential clinical applications. Adv Clin Chem 2004; 38: 37-85.
13. Malla N, Sjoli S, Winberg JO, Hadler-Olsen E, Uhlin-Hansen L. Biological and pathobiological functions of gelatinase dimers and complexes. Connect Tissue Res 2008; 49: 180-184.
14. Raffetto JD, Khalil RA. Matrix metalloproteinases in venous tissue remodeling and varicose vein formation. Curr Vasc Pharmacol 2008; 6: 158-172.
15. Raffetto JD, Khalil RA. Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease. Biochem Pharmacol 2008; 75: 346-359.
16. Mannello F. Serum or plasma samples? The Cinderella role of blood collection procedures: preanalytical methodological issues influence the release and activity of circulating matrix metallopro-teinases and their tissue inhibitors, hampering diagnostic trueness and leading to misinterpretation. Arterioscler Thromb Vasc Biol 2008; 28: 611-614.
17. Jung K, Klotzek S, Stephan C, Mannello F, Lein M. Impact of blood sampling on the circulating matrix metalloproteinases 1, 2, 3, 7, 8, and 9. Clin Chem 2008; 54: 772-3.
18. Mannello F, Tanus-Santos JE, Meschiari CA, Tonti GA. Differences in both matrix metalloproteinase 9 concentration and zy-mographic profile between plasma and serum with clot activators are due to the presence of amorphous silica or silicate salts in blood collection devices. Anal Biochem 2008; 374: 56-63.
19. Mannello F, Jung K, Tonti GA, Canestrari F. Heparin affects matrix metalloproteinases and tissue inhibitors of metalloproteinases circulating in peripheral blood. Clin Biochem 2008; 41: 1466-1473.
20. Lauver DA, Lucchesi BR. Sulodexide: a renewed interest in this glycosaminoglycan. Cardiovasc Drug Rev 2006; 24: 214-226.
21. Ofosu FA. Pharmacological actions of sulodexide. Semin Thromb Hemost 1998; 24: 127-138.
22. Mannello F, Raffetto JD. Matrix metalloproteinase activity and glycosaminoglycans in chronic venous disease: the linkage among cell biology, pathology and translational research. Am J Transl Res 2011; 3: 149-158.
23. Raffetto JD. Dermal pathology, cellular biology, and inflammation in chronic venous disease. Thromb Res 2009; 123 (Suppl 4): S66-S71.
24. Raffetto JD, Ross RL, Khalil RA. Matrix metalloproteinase 2-induced venous dilation via hyperpolarization and activation of K+ channels: relevance to varicose vein formation. J Vasc Surg 2007; 45: 373-380.
25. Bergan JJ, Schmid-Schonbein GW, Smith PD, Nicolaides AN, Boisseau MR, Eklof B. Chronic venous disease. N Engl J Med 2006; 355: 488-498.
26. Fiebig A, Krusche P, Wolf A, et al. Heritability of chronic venous disease. Hum Genet 2010; 127: 669-674.
27. Coccheri S, Scondotto G, Agnelli G, Aloisi D, Palazzini E, Zam-boni V. Randomised, double blind, multicentre, placebo controlled study of sulodexide in the treatment of venous leg ulcers. Thromb Haemost 2002; 87: 947-952.
28. Scondotto G, Aloisi D, Ferrari P, Martini L. Treatment of venous leg ulcers with sulodexide. Angiology 1999; 50: 883-889.
29. Mannello F, Luchetti F, Canonico B, Falcieri E, Papa S. Measurements, zymographic analysis, and characterization of matrix metal-loproteinase-2 and -9 in healthy human umbilical cord blood. Clin Chem 2004; 50: 1715-1717.
30. Mannello F. Effects of blood collection methods on gelatin zy-mography of matrix metalloproteinases. Clin Chem 2003; 49: 339-340.
31. Gazzanelli G, Luchetti F, Burattini S, Mannello F, Falcieri E, Papa S. Matrix metalloproteinases expression in HL-60 promyelocytic leukemia cells during apoptosis. Apoptosis 2000; 5: 165-172.
32. Makowski GS, Ramsby ML. Use of citrate to minimize neutrophil matrix metalloproteinase-9 in human plasma. Anal Biochem 2003; 322: 283-286.
33. Mannello F, Jung K, Tonti GA, Canestrari F. Heparin affects matrix metalloproteinases and tissue inhibitors of metalloproteinases circulating in peripheral blood. Clin Biochem 2008; 41: 1466-1473.
34. Mannello F, Luchetti F, Canonico B, Papa S. Effect of anticoagulants and cell separation media as preanalytical determinants on zymographic analysis of plasma matrix metalloproteinases. Clin Chem 2003; 49: 1956-1957.
35. Mannello F, Tonti GA, Tanus-Santos JE, Gerlach RF. Silicate increases the release of MMP-9 forms in peripheral blood: why gelatin zymography differs significantly in citrate plasma and serum obtained with or without clot activators. Clin Chem 2007; 53: 1981-1982.
36. Gerlach RF, Demacq C, Jung K, Tanus-Santos JE. Rapid separation of serum does not avoid artificially higher matrix metalloprote-inase (MMP)-9 levels in serum vs. plasma. Clin Biochem 2007; 40: 119-123.
37. Errichi BM, Cesarone MR, Belcaro G, et al. Prevention of recurrent deep venous thrombosis with sulodexide: the SanVal registry. Angiology 2004; 55: 243-249.
38. Coccheri S, Scondotto G, Agnelli G, Palazzini E, Zamboni V. Sulodexide in the treatment of intermittent claudication. Results of a randomized, double-blind, multicentre, placebo-controlled study. Eur Heart J 2002; 23: 1057-1065.
39. Loftus IM, Thompson MM. The role of matrix metalloproteinases in vascular disease. Vasc Med 2002; 7: 117-133.
40. Lijnen HR. Metalloproteinases in development and progression of vascular disease. Pathophysiol Haemost Thromb 2003; 33: 275-281.
41. Stack MS, Gray RD. Comparison of vertebrate collagenase and gelatinase using a new fluorogenic substrate peptide. J Biol Chem 1989; 264: 4277-4281.
42. Knight CG, Willenbrock F, Murphy G. A novel coumarin-labelled peptide for sensitive continuous assays of the matrix metalloprote-inases. FEBS Lett 1992; 296: 263-266.
43. Achilli C, Ciana A, Balduini C, Risso A, Minetti G. Application of gelatin zymography for evaluating low levels of contaminating neutrophils in red blood cell samples. Anal Biochem 2011; 409: 296-297.
44. Opdenakker G, Van den Steen PE, Van DJ. Gelatinase B: a tuner and amplifier of immune functions. Trends Immunol 2001; 22: 571-579.
45. Fernandez-Patron C, Martinez-Cuesta MA, Salas E, et al. Differential regulation of platelet aggregation by matrix metalloproteinases-9 and -2. Thromb Haemost 1999; 82: 1730-1735.
46. Mollinedo F, Nakajima M, Llorens A, et al. Major co-localization of the extracellular-matrix degradative enzymes heparanase and ge-latinase in tertiary granules of human neutrophils. Biochem J 1997; 327: 917-923.
47. Van den Steen PE, Dubois B, Nelissen I, Rudd PM, Dwek RA, Opdenakker G. Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9). Crit Rev Biochem Mol Biol 2002; 37: 375-536.
48. Nicolaides AN. Chronic venous disease and the leukocyte-endothelium interaction: from symptoms to ulceration. Angiology 2005; 56 (Suppl 1): S11-S19.
49. Raffetto JD, Marston WA. Venous ulcer: what is new? Plast Re-constr Surg 2011; 127 (Suppl 1): 279S-88S.
50. Andreozzi GM. Sulodexide in the treatment of chronic venous disease. Am J Cardiovasc Drugs 2012; 12: 73-81.